FRONTAGE (01521) has released its financial results for the year ended December 31, 2025. The group reported revenue of $257 million, representing a slight increase of 0.7% year-over-year. Profit attributable to the company's owners was $6.793 million, a significant surge of 758.8% compared to the previous year. Basic earnings per share stood at $0.0034.

According to the announcement, revenue from North American and European operations saw a minor decline, primarily due to a decrease in income generated from drug discovery services. This was negatively impacted by pharmaceutical and biotechnology companies continuing to optimize their research and development portfolios and maintaining cautious control over development expenditures. However, the decrease was partially offset by robust demand for laboratory testing services.

Revenue growth in the Chinese business was mainly driven by improved capacity utilization and the group's enhanced marketing efforts.